Fluid Results. Long-term skin hydration may be more achievable for your patients with SkinMedica's Hydrating Complex, a new serum containing high and low molecular weight hyaluronic acid (HA). The inclusion of both high and low weight HA provides instant hydration and restores the moisture reservoir beneath the skin, the company says. In a recent study, 45 women with self-perceived normal to dry skin used Hydrating Complex for 28 days. All patients reported their skin feeling softer, while 94 percent said the product improved the hydration of the skin. Additionally, a similar percentage of subjects observed an improvement in smoothness and moisture level in their skin.
Compliance with Combination. In efforts to enhance overall skincare and promote compliance with rosacea therapy, Intendis has joined with Coria to introduce Finacea Plus. Finacea Plus couples Finacea (azelaic acid gel 15%, Intendis) with CeraVe Moisturizing Lotion and CeraVe Hydrating Cleanser (Coria Laboratories, 3 oz. each) in a single package. The package includes educational materials for patients, along with a $10 coupon off a prescription of Finacea and a coupon for $2 toward the purchase of either CeraVe product.
Full Service. Your patients with African American, Latin, or Asian skin tones may be interested in the specially formulated skin care products available in Dr. Susan Taylor's Rx for Brown Skin line, distributed by Neutraderm for in-office dispensing. The line, developed by dermatologist Susan Taylor, MD, is formulated without potentially irritating ingredients like fragrance, lanolin, alcohol, propylene glycol, and dye. Four primary regimens form the basis of the line: Bright and Healthy Ultra-Gentle Regimen, Bright and Clear Acne Regimen featuring salicylic acid and botanical extracts, Exfoliating Regimen including glycolic acid, and Bright and Even Eye Cream with tyrostat-11 (a botanical agent). For more information, visit neutraderm.com.
New and Impruved. Two products popular with dermatologists and patients in Europe are now available to your patients due to the launch of Impruv Natural Repair Lotion and Impruv Natural Repair Cream from Stiefel Laboratories' US Consumer HealthCare Division. Featuring DMS or Derma Membrane Structure technology, the products-known as Physiogel Lotion and Physiogel Cream overseas-are designed to restore cutaneous lipids through incorporation of six botanicals, including coconut, palm, and olive oils, wheat germ, soy, and shea butter, the company says. Products will be distributed through Walgreens stores nationwide and are suitable for use on mild to severe dry skin.
Several other classic Stiefel Consumer products will be reintroduced as part of the Impruv line, including Impruv Moisturizing Antibacterial Cleanser (formerly Oilatum AD) and Impruv Dep Moisturizing Lotion (formerly LactiCare).
Serve and Protect. Recognizing that protection is essential to sun safety, Glytone's physician-exclusive sun care product line recently expanded to include Sunscreen Lotion SPF 30 and Sunscreen Lotion SPF 40. Both products offer UVA/UVB mineral-based protection suitable for all skin types, are fragrance-, and irritant-free, and guard against sunburn and photodamage.
Bottled Up. For patients treating larger surface areas or requiring longer courses of topical corticosteroid therapy, consider prescribing the new 4oz. bottle of Locoid Lipocream (Triax), launched last month. The 2oz. bottle of the mid-potency corticosteroid is still available. Don't be surprised when your Intendis rep discusses the product with you; the company has teamed with Triax on promotion of the drug.
IN THE PIPELINE
A new botulinum toxin filler is nearing the market. Medicis and Ipsen recently re-filed a New Drug Application with the FDA for the approval of Reloxin (botulinum toxin, type A), which is currently marketed overseas.
Coinciding with the submission is the release of recent data indicating the agent's generally high tolerability and ability to reduce forehead wrinkles (Archives of Facial Plastic Surgery, March/April 2009). As reported by Ipsen, in a phase III, open-label study of 1,200 patients, researchers injected 0.05 milliliters of solution, each containing 10 units of botulinum toxin A, into each of five injection sites in the forehead at the beginning of each treatment cycle. Patients maintained diaries of treatment effects, were telephoned seven days after injection to check for adverse events, and were re-examined clinically after two weeks, 30 days, and again every month until their next treatment, withdrawal from the study, or conclusion of the study. As many as five consecutive treatments were given with a minimum of 85 days in between.
A total of 1,052 patients completed the 13-month study. During the study period, 880 patients experienced a total of 2,838 adverse events. Of those, 28 percent were considered probably or possibly related to treatment, including events at the injection site (18 percent), nervous system disorders (14 percent), headache (12 percent), and eye events (nine percent overall, including four percent with ptosis). One percent of patients discontinued therapy because of adverse events.
Investigators concluded that multiple cycles of treatment with 50 units of botulinum type A toxin were well tolerated and maintained a clinical effect over 13 months and that the incidence of treatment-emergent adverse events decreased over time.